Trending Stock News

Dollar Gen New (DG) Holder Polen Capital Management Has Raised Its Holding by $12.55 Million as Shares Declined; As Macrogenics (MGNX) Valuation Declined, Bb Biotech Ag Has Lifted Its Stake by $905,400

Polen Capital Management Llc increased its stake in Dollar Gen Corp New (DG) by 3.24% based on its latest 2017Q3 regulatory filing with the SEC. Polen Capital Management Llc bought 154,938 shares as the company’s stock declined 7.36% while stock markets rallied. The institutional investor held 4.94 million shares of the department and specialty retail stores company at the end of 2017Q3, valued at $400.04M, up from 4.78M at the end of the previous reported quarter. Polen Capital Management Llc who had been investing in Dollar Gen Corp New for a number of months, seems to be bullish on the $26.91B market cap company. The stock increased 0.93% or $0.91 during the last trading session, reaching $99.1. About 2.33 million shares traded. Dollar General Corporation (NYSE:DG) has declined 12.26% since January 14, 2017 and is downtrending. It has underperformed by 28.96% the S&P500.

Bb Biotech Ag increased its stake in Macrogenics Inc. (MGNX) by 2.14% based on its latest 2017Q3 regulatory filing with the SEC. Bb Biotech Ag bought 50,300 shares as the company’s stock declined 10.05% while stock markets rallied. The institutional investor held 2.40M shares of the health care company at the end of 2017Q3, valued at $44.36 million, up from 2.35 million at the end of the previous reported quarter. Bb Biotech Ag who had been investing in Macrogenics Inc. for a number of months, seems to be bullish on the $755.97 million market cap company. The stock increased 5.55% or $1.08 during the last trading session, reaching $20.53. About 354,983 shares traded or 19.99% up from the average. MacroGenics, Inc. (NASDAQ:MGNX) has declined 9.76% since January 14, 2017 and is downtrending. It has underperformed by 26.46% the S&P500.

Bb Biotech Ag, which manages about $3.61 billion US Long portfolio, decreased its stake in Juno Therapeutics Inc. (NASDAQ:JUNO) by 130,000 shares to 2.06M shares, valued at $92.19 million in 2017Q3, according to the filing.

Among 10 analysts covering MacroGenics (NASDAQ:MGNX), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. MacroGenics had 20 analyst reports since August 6, 2015 according to SRatingsIntel. Zacks downgraded MacroGenics, Inc. (NASDAQ:MGNX) on Monday, August 10 to “Buy” rating. Morgan Stanley initiated MacroGenics, Inc. (NASDAQ:MGNX) rating on Thursday, February 25. Morgan Stanley has “Equal-Weight” rating and $20 target. The rating was initiated by SunTrust on Tuesday, December 20 with “Buy”. The rating was initiated by Citigroup with “Neutral” on Thursday, September 17. The stock of MacroGenics, Inc. (NASDAQ:MGNX) earned “Neutral” rating by Citigroup on Thursday, August 4. The firm earned “Equal-Weight” rating on Monday, August 7 by Morgan Stanley. The rating was maintained by Stifel Nicolaus on Monday, September 11 with “Buy”. As per Thursday, August 6, the company rating was maintained by Stifel Nicolaus. The firm earned “Buy” rating on Thursday, February 18 by Janney Capital. BTIG Research maintained the shares of MGNX in report on Wednesday, October 25 with “Buy” rating.

Investors sentiment decreased to 1.58 in 2017 Q3. Its down 0.15, from 1.73 in 2017Q2. It turned negative, as 7 investors sold MGNX shares while 26 reduced holdings. 11 funds opened positions while 41 raised stakes. 27.72 million shares or 0.96% more from 27.45 million shares in 2017Q2 were reported. State Board Of Administration Of Florida Retirement has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Royal Savings Bank Of Canada has 3,847 shares for 0% of their portfolio. 2,500 are held by Great West Life Assurance Can. Tiaa Cref Inv Mngmt owns 89,212 shares. First Light Asset Mngmt Limited Company has invested 0.89% in MacroGenics, Inc. (NASDAQ:MGNX). Ubs Asset Management Americas holds 0.01% or 371,144 shares in its portfolio. Alps Advsrs stated it has 0% in MacroGenics, Inc. (NASDAQ:MGNX). Blackrock holds 2.69 million shares or 0% of its portfolio. Northern Tru holds 430,363 shares or 0% of its portfolio. Perigon Wealth Mngmt Lc owns 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 100 shares. Citigroup Inc owns 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 17,029 shares. Manufacturers Life The reported 26,495 shares. Cornerstone Capital Mgmt Hldgs Ltd Liability Co invested 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). California State Teachers Retirement System reported 54,213 shares or 0% of all its holdings. Amer Intl Gp reported 22,305 shares stake.

Since October 25, 2017, it had 0 insider buys, and 1 sale for $200,000 activity.

Since September 12, 2017, it had 0 insider buys, and 5 selling transactions for $3.04 million activity. Shares for $251,895 were sold by TAYLOR RHONDA on Tuesday, December 12. 2,012 Dollar General Corporation (NYSE:DG) shares with value of $186,747 were sold by ELLIOTT ANITA C. 7,536 shares were sold by Kindy Michael J, worth $683,092.

Among 29 analysts covering Dollar General Corp. (NYSE:DG), 14 have Buy rating, 3 Sell and 12 Hold. Therefore 48% are positive. Dollar General Corp. had 96 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Dollar General Corporation (NYSE:DG) earned “Buy” rating by Goldman Sachs on Monday, March 28. The company was maintained on Friday, September 1 by Jefferies. The stock has “Hold” rating by KeyBanc Capital Markets on Tuesday, October 3. Credit Suisse maintained it with “Outperform” rating and $95 target in Friday, May 27 report. Johnson Rice downgraded the shares of DG in report on Friday, August 26 to “Accumulate” rating. The rating was maintained by UBS on Friday, August 26 with “Buy”. As per Wednesday, April 19, the company rating was maintained by Buckingham Research. The stock of Dollar General Corporation (NYSE:DG) has “Peer Perform” rating given on Tuesday, November 10 by Wolfe Research. The rating was maintained by Deutsche Bank with “Hold” on Friday, August 26. Deutsche Bank maintained the stock with “Buy” rating in Wednesday, October 7 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *